Speaking at the 16th annual meeting of the Medical Device Manufacturer's Association (MDMA), the organization's president and CEO, Mark Leahey, stressed the importance of engaging both FDA and politicians. “If the United States is to maintain its leadership position in medical technology innovation, we must have a reasonable and predictable regulatory pathway and not impose taxes on the very companies that are developing the cures of tomorrow. We will continue to work with Congressional and agency leaders to ensure that patients have timely access to safe and effective products and that innovation continues to flourish.”

Chairman of MDMA, Eamonn Hobbs, also highlighted the importance of government policies. "It is essential that government officials support policies that promote innovation and entrepreneurship so that we may continue to develop the next generation of technologies and therapies that will allow patients to live longer, more productive lives," he said.

High ranking FDA officials were present at the event. FDA principal deputy commissioner Joshua Sharfstein delivered a keynote address and Jeffrey Shuren, CDRH director, participated in a question and answer session.